Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 1, Pages e80836
Publisher
Public Library of Science (PLoS)
Online
2014-01-14
DOI
10.1371/journal.pone.0080836
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells
- (2014) Arnim Weber et al. Translational Oncology
- Patient-derived xenografts recapitulate molecular features of human uveal melanomas
- (2013) Cécile Laurent et al. Molecular Oncology
- Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1
- (2012) Henry Zall et al. Molecular Cancer
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
- (2011) S. Al-harbi et al. BLOOD
- ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents
- (2011) Cyrille Touzeau et al. CLINICAL CANCER RESEARCH
- Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
- (2011) K. M. Lucas et al. CLINICAL CANCER RESEARCH
- Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models
- (2011) Nguyen Tan et al. CLINICAL CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1
- (2011) C. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- BH3 mimetics activate multiple pro-autophagic pathways
- (2011) S A Malik et al. ONCOGENE
- The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53
- (2011) Steven N. Reuland et al. PLoS One
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Molecular Basis of Synergism between Carboplatin and ABT-737 Therapy Targeting Ovarian Carcinomas
- (2010) H. V. Jain et al. CANCER RESEARCH
- Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines
- (2010) H. Xu et al. CLINICAL CANCER RESEARCH
- Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
- (2010) F. Nemati et al. CLINICAL CANCER RESEARCH
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The Pan-Bcl-2 Inhibitor (-)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma
- (2010) V. Voss et al. MOLECULAR CANCER RESEARCH
- Effectiveness of Treatments for Metastatic Uveal Melanoma
- (2009) James J. Augsburger et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non-Small Cell Lung Tumor Xenograft Model
- (2009) K. W. Kim et al. CLINICAL CANCER RESEARCH
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
- (2009) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
- (2009) Asher A. Chanan-Khan et al. LEUKEMIA & LYMPHOMA
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients
- (2008) Verena Voelter et al. MELANOMA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started